Why Degradation Pathways Matter

Every API undergoes degradation to some extent over time. Regulatory authorities such as EMA and CDSCO require evidence that drug products remain safe and effective throughout their shelf life. To meet these expectations, manufacturers must identify degradation mechanisms, evaluate impurity profiles, and quantify degradation rates under various storage conditions.

These pathways influence not just expiry dates but also packaging, labeling, and formulation strategies. In addition, ICH guidelines such as Q1A(R2), Q1B, and Q3A/B provide frameworks for evaluating degradation-related risks.

Common API Degradation Mechanisms

Let’s look at the five most prevalent pathways through which APIs degrade:

1. Hydrolysis: Cleavage of chemical bonds by water, common in esters, amides, and lactams.
2. Oxidation: Involves electron transfer, often affects phenols, alcohols, and amines.
3. Photolysis: Light-induced degradation, especially with APIs containing conjugated systems.
4. Thermal Degradation: Heat-sensitive APIs break down under high temperatures.
5. Racemization: Chiral molecules interconvert into inactive or toxic isomers.

Understanding which pathway predominates enables you to tailor formulation and packaging decisions accordingly. For example, highly oxidizable APIs may require antioxidant inclusion or nitrogen flushing in containers.

Forced Degradation and Impurity Profiling

Forced degradation (also known as stress testing) is an integral part of stability evaluation. It helps to:

• ✅ Identify degradation products
• ✅ Establish degradation pathways
• ✅ Validate stability-indicating analytical methods

Typically, APIs are subjected to the following stress conditions:

• ✅ Acidic and basic hydrolysis
• ✅ Oxidative conditions (e.g., H₂O₂)
• ✅ UV/Visible light exposure
• ✅ Elevated temperatures (e.g., 60–80°C)
• ✅ High humidity (>75% RH)

The degradation products are then evaluated against the limits defined in regulatory compliance standards, and shelf life is set such that impurities remain within acceptable thresholds.

Kinetics of Degradation: First-Order vs. Zero-Order

Degradation kinetics influence expiry prediction models. Most APIs follow either first-order or zero-order kinetics.

• First-order: Rate of degradation depends on the concentration of API (common for solutions).
• Zero-order: Constant degradation rate independent of concentration (common for suspensions).

Shelf life (t₉₀) can be predicted using the equation:

t₉₀ = 0.105/k for first-order reactions

Here, k is the rate constant derived from accelerated stability data. Statistical modeling tools help extrapolate this to real-time conditions.

For more on predictive modeling, explore shelf life modeling tools and validation.

Container-Closure Influence on Degradation

The choice of packaging can significantly impact degradation rates. Consider:

• ✅ Amber bottles for photolabile APIs
• ✅ Desiccants and foil blisters for moisture-sensitive compounds
• ✅ Oxygen-impermeable materials for oxidizable APIs

Conduct extractable/leachable studies and simulate storage conditions to ensure compatibility between the container and drug product.

Stability Data and Expiry Dating

Expiry dating decisions are made based on real-time and accelerated stability data collected at predetermined intervals (e.g., 0, 3, 6, 9, 12 months). According to ICH Q1A(R2), acceptable statistical methods should be used to analyze the data, and a retest or expiry period is set when the product still meets all specifications.

Data must be generated at both ICH Zone II and Zone IVb conditions (25°C/60%RH and 30°C/75%RH) to support shelf life in different regions.

Labeling and Regulatory Submissions

Once degradation pathways and shelf life are established, the final expiry date and storage conditions must be included in the product labeling. Typical statements include:

• ✅ “Store below 25°C”
• ✅ “Protect from light and moisture”
• ✅ “Use within 30 days of opening”

In CTD submissions, Module 3.2.P.8.1 and 3.2.P.8.3 must include comprehensive stability data, degradation studies, and justification for the expiry period.

Degradation Impact Summary Table

Conclusion

API degradation is inevitable but manageable. Understanding degradation pathways allows pharmaceutical professionals to control risks, select optimal packaging, comply with global regulations, and most importantly, protect patients. Whether through analytical profiling, statistical modeling, or thoughtful packaging, expiry dating must reflect robust scientific understanding of API behavior.

References:

• ICH Quality Guidelines
• WHO Technical Reports
• SOPs for degradation testing and stability programs
• GMP principles for storage and stability

Why Global Consistency in Expiry Terminology Matters

Multinational pharmaceutical companies often market the same product across various regions. However, expiry-related terms may differ in meaning between jurisdictions:

• ❌ “Retest date” may be accepted in one region and rejected in another
• ❌ Shelf life vs. expiry might be used interchangeably, causing confusion
• ❌ Inconsistent use of terms across dossiers can result in questions during review

To harmonize these differences, the ICH and WHO have developed structured guidance.

ICH Interpretation of Expiry Terminology

The International Council for Harmonisation (ICH) provides guidance primarily through ICH Q1A(R2), Q1B, and Q7. Key definitions include:

• Shelf Life: The time period during which a drug product is expected to remain within approved specifications, stored under defined conditions.
• Expiry Date: The date placed on the label designating the time during which the product is expected to remain stable.
• Retest Date: The date by which an API should be re-examined to ensure it is still suitable for use.

Key Point: ICH encourages using “retest date” for APIs and “expiry date” for finished products, as detailed in ICH Q7.

WHO Interpretation of Expiry Terminology

The World Health Organization (WHO), through its stability and prequalification guidelines, aligns closely with ICH definitions but adds clarity in global health contexts.

According to WHO:

• Expiry Date: The date after which the product is not guaranteed to remain within specifications and should not be used.
• Retest Date: For APIs, the date beyond which testing is required prior to further use, provided storage is under defined conditions.
• Labeling Requirements: WHO explicitly requires clear indication of expiry or retest date depending on material type and regulatory filing.

WHO also emphasizes expiry control as a GMP principle, especially for medicines supplied through procurement programs.

Case Comparison: API Labeling for Retest vs Expiry

Consider a bulk API manufactured in India and exported to the EU and Africa. The same material may be labeled as follows:

• ✅ For EU (ICH territory): “Retest date: MM/YYYY”
• ✅ For WHO procurement: “Expiry date: MM/YYYY” based on receiving country’s guideline

This dual terminology must be addressed in regulatory documentation, quality agreements, and COAs.

For guidance on aligning terminology in SOPs, see Pharma SOPs best practices.

Common Challenges with Expiry Terminology

• ❌ Labeling APIs with both expiry and retest dates inconsistently
• ❌ Not updating ERP master data to reflect ICH-compliant terms
• ❌ Misinterpreting WHO’s requirement as mandatory expiry for all materials
• ❌ Using “shelf life” in documents without defining it clearly

Each of these can be addressed through cross-functional training and regulatory review.

Best Practices for Aligning with ICH and WHO

Here’s a checklist to align expiry terminology across your systems:

• ✅ Define “shelf life”, “retest date”, and “expiry date” in all SOPs
• ✅ Align ERP and labeling logic with ICH Q1A and Q7 terminology
• ✅ Use retest dates for APIs unless local regulation demands expiry
• ✅ Avoid using “shelf life” alone—tie it to a defined specification or condition
• ✅ Train Regulatory Affairs and QA on WHO vs. ICH interpretations

These steps help ensure consistency across labeling, submission documents, and inspection responses.

Integration in Dossiers and CTDs

In Common Technical Documents (CTDs), expiry and shelf life terms appear in Module 3 (Quality), particularly in sections:

• 3.2.P.8 – Stability Summary and Conclusion
• 3.2.S.7 – Stability of APIs
• Labeling section for Module 1 (country-specific)

Ensure terminology matches across modules and appendices to prevent delay in approvals.

Impact on Labeling and Packaging Control

Both WHO and ICH require clear labeling of expiry or retest dates on all containers:

• ✅ Finished Products: “Expiry date” is mandatory
• ✅ APIs: “Retest date” may be used unless national regulation states otherwise
• ✅ Secondary packaging must display the date clearly and be resistant to smearing or abrasion

Reconciliation of expiry labeling must be part of QA release procedures. For guidance, review GMP guidelines.

Table: Summary of Differences

Conclusion

Clear understanding and consistent application of expiry terminology—as defined by ICH and WHO—are vital for regulatory success, global compliance, and patient safety. While both organizations offer aligned guidance, their emphasis and context can vary depending on the type of product and country of sale.

Pharma professionals should ensure SOPs, ERP systems, submission documents, and labels reflect harmonized terminology, supported by sound stability data and regulatory knowledge.

References:

• ICH Q1A(R2), Q1B, Q7
• WHO Technical Report Series: Stability Guidelines
• CDSCO Expiry Labeling Rules
• USFDA Labeling and Expiry FAQs